Newsroom
Sight Sciences Introduces the Next-Generation OMNI® Surgical System for Microinvasive Glaucoma Surgery
Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest-growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced the launch of its next-generation OMNI Surgical System for microinvasive glaucoma surgery (MIGS) procedures.
Sight Sciences Announces Publication of Historical Review of Canal Surgery in the Glaucoma Issue of Current Opinion in Ophthalmology
MENLO PARK, Calif., March 30, 2020 /PRNewswire/ -- Sight Sciences, Inc., a growth-stage medical device company focused on transforming the treatment of glaucoma and dry eye disease, today announced that a review of the history of canal surgery in glaucoma, by Jaime Dickerson, Ph.D., and Reay Brown, M.D., has been published in Current Opinion in Ophthalmology.
Sight Sciences Announces Publication of First-Ever Multicenter MIGS study in Childhood Glaucoma
Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest-growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced that positive outcomes from a new multicenter study of one of the OMNI® Surgical System’s predecessor devices, TRAB®360, were published in the American Journal of Ophthalmology. Following a 2019 publication1 of a […]
Sight Sciences Expands Surgical Portfolio with FDA Clearance of the OMNI™ Surgical System
Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic device company, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its OMNI™ Surgical System, a surgical tool dually indicated for the delivery of controlled volumes of viscoelastic fluid as well as the cutting of trabecular meshwork tissue. In addition, the company announced three key […]
Clinical Study Demonstrates Long Term IOP Reduction With The OMNI™ Surgical System Predicate Device (TRAB™360) In Micro-Invasive Glaucoma Surgery
A new, single center retrospective study of glaucoma surgery patients published in the January 2019 issue of Clinical Ophthalmology shows that ab-interno trabeculotomy using one of Sight Sciences’ OMNI™ Surgical System’s Predicate Devices (TRAB™360) provides a favorable safety profile and substantial long-term reductions in both intraocular pressure (IOP) and IOP-lowering medications. Conducted by Steven Sarkisian, […]
First Subjects Enrolled in Clinical Study to Evaluate Safety and Efficacy of OMNI™ Surgical System for Multiple Micro-Invasive Glaucoma Surgery Procedures
MENLO PARK, Calif. – Sight Sciences today announced enrollment has begun in the Gemini clinical study, a Sight Sciences-sponsored, prospective, multi-center study to evaluate the safety and efficacy of the OMNI™ Surgical System in performing two sequential Micro-Invasive Glaucoma Surgery (MIGS) procedures – transluminal viscoelastic delivery and trabeculotomy. Subjects must have mild-to-moderate primary open angle glaucoma […]
Sight Sciences Announces Official Launches of TearCare™ and the Enhanced, Next Generation OMNI™ System
New Dry Eye and MIGS Entrants will be Prominently Featured in Product Demonstrations and Events at Upcoming Industry Shows MENLO PARK, Calif. – Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry – dry eye and glaucoma – today announced the official commercial launch of TearCare™ […]